The weight of evidence supports a role in dementia risk reduction, particularly among individuals with diabetes, obesity, metabolic syndrome, or APOE 4 risk
Hadidchi carefully evaluates each patients medical history, metabolic health, and personal preferences before recommending any prescription therapy, including GLP-1 medications, as part of a comprehensive treatment plan
GPX4 competitively inhibits the production of ROS
Con: Since most of what you take is digested instead of absorbed, it can feel like a waste
doi: 10.1124/pr.108.000604, 81 KlausenM
In retatrutides TRIUMPH-1 trial, participants were titrated toward one of three target doses 4 mg, 9 mg, or 12 mg with the highest dose associated with the greatest weight loss and the greatest rate of GI side effects